- Home
- TLRY vs BCYC Comparison
TLRY vs BCYC Comparison
Compare TLRY & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLRY
- BCYC
- Stock Information
- Founded
- TLRY N/A
- BCYC 2009
- Country
- TLRY Canada
- BCYC United Kingdom
- Employees
- TLRY N/A
- BCYC N/A
- Industry
- TLRY Medicinal Chemicals and Botanical Products
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- TLRY Health Care
- BCYC Health Care
- Exchange
- TLRY Nasdaq
- BCYC Nasdaq
- Market Cap
- TLRY 637.2M
- BCYC 511.4M
- IPO Year
- TLRY 2018
- BCYC 2019
- Fundamental
- Price
- TLRY $0.45
- BCYC $7.39
- Analyst Decision
- TLRY Hold
- BCYC Buy
- Analyst Count
- TLRY 4
- BCYC 8
- Target Price
- TLRY $1.58
- BCYC $29.14
- AVG Volume (30 Days)
- TLRY 26.1M
- BCYC 438.9K
- Earning Date
- TLRY 04-08-2025
- BCYC 05-01-2025
- Dividend Yield
- TLRY N/A
- BCYC N/A
- EPS Growth
- TLRY N/A
- BCYC N/A
- EPS
- TLRY N/A
- BCYC N/A
- Revenue
- TLRY $826,656,000.00
- BCYC $35,275,000.00
- Revenue This Year
- TLRY $11.80
- BCYC N/A
- Revenue Next Year
- TLRY $5.41
- BCYC $0.27
- P/E Ratio
- TLRY N/A
- BCYC N/A
- Revenue Growth
- TLRY 11.22
- BCYC 30.76
- 52 Week Low
- TLRY $0.43
- BCYC $6.10
- 52 Week High
- TLRY $2.52
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- TLRY 29.90
- BCYC 40.27
- Support Level
- TLRY $0.46
- BCYC $6.10
- Resistance Level
- TLRY $0.52
- BCYC $8.00
- Average True Range (ATR)
- TLRY 0.05
- BCYC 0.61
- MACD
- TLRY -0.01
- BCYC 0.14
- Stochastic Oscillator
- TLRY 8.33
- BCYC 46.07
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.